1.
J Cardiovasc Pharmacol
; 80(6): 781-782, 2022 12 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36027584
RESUMEN
ABSTRACT: Atrial fibrillation is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. Polypharmacotherapy is crucial in atrial fibrillation management, and in many of the concomitant comorbidities, such as hypertension, heart failure, coronary artery disease, and diabetes. However, polypharmacy represents a major concern because of the associated risks of adverse events onset, with an increased risk of all-cause mortality and cardiovascular mortality. In this study, we commented data reported by Tsagkaris et al comparing them with previous reports.
Asunto(s)
Fibrilación Atrial , Humanos , Anciano de 80 o más Años , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/epidemiología
2.
J Cardiovasc Pharmacol
; 83(2): 131-133, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37890467
3.
J Cardiovasc Pharmacol
; 81(6): 395-396, 2023 06 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36995098